Ontology highlight
ABSTRACT:
SUBMITTER: Sugumar D
PROVIDER: S-EPMC4325627 | biostudies-other | 2015
REPOSITORIES: biostudies-other
Pharmacogenomics and personalized medicine 20150120
Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved in the US in 2012 as single-agent therapy for relapsed and refractory multiple myeloma. Numerous Phase II studies have evaluated carfilzomib in the relapsed and refractory as well as the newly diagnosed setting, and Phase III studies are entering their final analysis. Data continue to grow to support its use as both single-agent therapy and in combination with immunomodulatory and other novel agents. This review di ...[more]